3-氰基-苯丙酸甲酯 | 193151-11-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氰基-苯丙酸甲酯
• 中文别名: (3-氰基苯基)丙酸甲酯
• 英文名称: methyl 3-(3-cyanophenyl)propanoate
• 英文别名: 3-(3-cyano-phenyl)-propionic acid methyl ester；methyl 3-(3-cyanophenyl)propionate；methyl (3-cyanophenyl)propanoate
• CAS: 193151-11-0
• 化学式: C₁₁H₁₁NO₂
• 分子量: 189.214
• InChiKey: YPAZQTSKIDBDAQ-UHFFFAOYSA-N

物化性质

• 沸点：
  298℃
• 密度：
  1.11
• 闪点：
  137℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  50.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-氰基-苯丙酸甲酯 在 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 2.0h， 生成 3-氰基苯丙酸
  参考文献：
  名称：

  Identification and Initial Structure−Activity Relationships of a Novel Class of Nonpeptide Inhibitors of Blood Coagulation Factor Xa

  摘要：

  The discovery and some of the basic structure-activity relationships of a series of novel nonpeptide inhibitors of blood coagulation Factor Xa is described. These inhibitors are functionalized p-alanines, exemplified by 2a. Docking experiments placing 2a in the active site of Factor Xa implied that the Most expeditious route to enhancing in vitro potency was to modify the group occupying the S3 site of the enzyme. Increasing the hydrophobic contacts between the inhibitor and the enzyme in this region led to 8, which has served as the prototype for this series. In addition, an enantioselective synthesis of these substituted p-alanines was also developed.

  DOI：

  10.1021/jm970482y
• 作为产物：
  描述：

  3-(3-羟苯基)丙酸甲酯 在 四(三苯基膦)钯 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 31.0h， 生成 3-氰基-苯丙酸甲酯
  参考文献：
  名称：

  3,4,5-Trisubstituted isoxazoles as novel PPARδ agonists. Part 2

  摘要：

  A series of PPARdelta-selective agonists was investigated and optimized for a favorable in vivo pharmacokinetic profile. Isoxazole LCI765 (17d) was found to be a potent and selective PPARdelta agonist with good in vivo PK properties in mouse (C(max)=5.1 microM, t(1/2)=3.1 h). LCI765 regulated expression of genes involved in energy homeostasis in relevant tissues when dosed orally in C57BL6 mice. A co-crystal structure of compound LCI765 and the LBD of PPARdelta is discussed.

  DOI：

  10.1016/j.bmcl.2006.08.052

文献信息

• Manganese-catalyzed homogeneous hydrogenation of ketones and conjugate reduction of α,β-unsaturated carboxylic acid derivatives: A chemoselective, robust, and phosphine-free in situ-protocol
  作者：Thomas Vielhaber、Christoph Topf

  DOI：10.1016/j.apcata.2021.118280

  日期：2021.8

  glove-box-free catalytic protocol for the manganese-catalyzed hydrogenation of ketones and conjugated CCbonds of esters and nitriles. The respective catalyst is readily assembled in situ from the privileged [Mn(CO)5Br] precursor and cheap 2-picolylamine. The catalytic transformations were performed in the presence of t-BuOK whereby the corresponding hydrogenation products were obtained in good to excellent yields

  我们传达了一种用户友好且无需手套箱的催化协议，用于酮和酯和腈的共轭 C C键的锰催化氢化。相应的催化剂很容易由特权 [Mn(CO) 5 Br] 前体和廉价的 2-吡啶甲胺原位组装。催化转化在t- BuOK存在下进行，从而以良好至极好的收率获得相应的氢化产物。所描述的系统提供了对仲醇和饱和酯的快速和原子效率的访问，避免了使用氧敏感和昂贵的基于膦的配体。
• Prostaglandin agonists and their use to treat bone disorders
  申请人：Pfizer Inc.

  公开号：US06498172B1

  公开（公告）日：2002-12-24

  This invention relates to prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.

  本发明涉及前列腺素受体激动剂、使用此类前列腺素受体激动剂的方法、含有此类前列腺素受体激动剂的药物组合物以及含有此类前列腺素受体激动剂的试剂盒。这些前列腺素受体激动剂可用于治疗包括骨质疏松症在内的骨骼疾病。
• Novel Compounds
  申请人：Theoclitou Maria-Elena

  公开号：US20080004302A1

  公开（公告）日：2008-01-03

  There is provided a compound of formula (I): processes for the manufacture thereof, pharmaceutical compositions thereof and uses in therapy.

  提供了一个化合物，其化学式为(I)：制备方法、药物组合物以及在治疗中的用途。
• Dual Ligand-Enabled Nondirected C–H Cyanation of Arenes
  作者：Hao Chen、Arup Mondal、Philipp Wedi、Manuel van Gemmeren

  DOI：10.1021/acscatal.8b04639

  日期：2019.3.1

  structural units in organic chemistry and, therefore, highly attractive targets for C–H activation. Herein, the development of an arene-limited, nondirected C–H cyanation based on the use of two cooperatively acting commercially available ligands is reported. The reaction enables the cyanation of arenes by C–H activation in the absence of directing groups and is therefore complementary to established

  芳香腈是有机化学中的关键结构单元，因此是C–H活化的极具吸引力的目标。在此，据报道，基于使用两种可协同作用的市售配体，开发了一种受芳烃限制的，无方向性的CH氰基氰化反应。该反应可在没有导向基团的情况下通过C–H活化使芳烃氰化，因此可与已建立的方法互补。
• [EN] PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF FGFR ACTIVITY<br/>[FR] DÉRIVÉS DE PYRIMIDINE ET LEUR UTILISATION EN TANT QUE MODULATEURS DE L'ACTIVITÉ DU FGFR
  申请人：ASTRAZENECA AB

  公开号：WO2009056886A1

  公开（公告）日：2009-05-07

  There is provided pyrimidine compounds of formula 1: or pharmaceutical salts thereof. There is al so provided processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy, for exampl e in the treatment of proliferative disease such as cancer and particular ly in disease mediated by a FGFR inhibitory effect.

  提供了化学式1的嘧啶化合物或其药用盐。还提供了其制备方法、含有它们的药物组合物、制备药物组合物的方法，以及它们在治疗中的应用，例如在治疗增殖性疾病如癌症以及由FGFR抑制作用介导的疾病中。